• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

    4/17/24 8:21:44 AM ET
    $AMGN
    $AR
    $BK
    $JBHT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Oil & Gas Production
    Energy
    Get the next $AMGN alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

    • HC Wainwright & Co. cut the price target for Unity Biotechnology, Inc. (NASDAQ:UBX) from $10 to $8. HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating. Unity Biotechnology shares gained 1.3% to close at $1.52 on Tuesday. See how other analysts view this stock.
    • TD Cowen slashed the price target for Amgen Inc. (NASDAQ:AMGN) from $370 to $360. TD Cowen analyst Yaron Weber maintained the stock with a Buy rating. Amgen shares rose 0.1% to close at $265.64 on Tuesday. See how other analysts view this stock.
    • B of A Securities cut Johnson & Johnson (NYSE:JNJ) price target from $180 to $170. B of A Securities analyst Geoff Meacham maintained a Neutral rating. Johnson & Johnson shares fell 2.1% to close at $144.45 on Tuesday. See how other analysts view this stock.
    • Morgan Stanley raised the price target for Antero Resources Corporation (NYSE:AR) from $26 to $36. Morgan Stanley analyst Devin McDermott upgraded the stock from Equal-Weight to Overweight. Antero Resources shares gained 0.4% to close at $29.12 on Tuesday. See how other analysts view this stock.
    • Stephens & Co. slashed J.B. Hunt Transport Services, Inc. (NASDAQ:JBHT) price target from $210 to $192. Stephens & Co. analyst Justin Long maintained an Overweight rating. J.B. Hunt Transport shares fell 1.1% to close at $182.99 on Tuesday. See how other analysts view this stock.
    • Truist Securities raised Strategic Education, Inc. (NASDAQ:STRA) price target from $110 to $125. Truist Securities analyst Tobey Sommer upgraded the stock from Hold to Buy. Strategic Education shares fell 0.6% to close at $96.71 on Tuesday. See how other analysts view this stock.
    • Jefferies lowered the price target for Urban Outfitters, Inc. (NASDAQ:URBN) from $42 to $32. Jefferies analyst Corey Tarlowe downgraded the stock from Hold to Underperform. Urban Outfitters shares fell 0.5% to close at $38.02 on Tuesday. See how other analysts view this stock.
    • RBC Capital cut Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) price target from $24 to $3. RBC Capital analyst Brian Abrahams downgraded the stock from Outperform to Sector Perform. Marinus Pharmaceuticals shares fell 7.7% to close at $1.20 on Tuesday. See how other analysts view this stock.
    • Baird boosted Visa Inc. (NYSE:V) price target from $314 to $320. Baird analyst David Koning maintained an Outperform rating. Visa shares rose 0.1% to close at $271.35 on Tuesday. See how other analysts view this stock.
    • B of A Securities raised The Bank of New York Mellon Corporation (NYSE:BK) price target from $64 to $66. B of A Securities analyst Ebrahim Poonawala maintained a Buy rating. Bank of New York Mellon shares fell 2% to close at $54.00 on Tuesday. See how other analysts view this stock.

     

    Check This Out: Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket

    Get the next $AMGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $AR
    $BK
    $JBHT

    CompanyDatePrice TargetRatingAnalyst
    Visa Inc.
    $V
    2/3/2026$370.00Neutral → Outperform
    Daiwa Securities
    Visa Inc.
    $V
    1/28/2026$385.00Neutral → Buy
    Rothschild & Co Redburn
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Visa Inc.
    $V
    1/27/2026$400.00Overweight
    Cantor Fitzgerald
    Amgen Inc.
    $AMGN
    1/20/2026$335.00Outperform → Mkt Perform
    Bernstein
    J.B. Hunt Transport Services Inc.
    $JBHT
    1/8/2026$221.00Buy → Neutral
    Citigroup
    J.B. Hunt Transport Services Inc.
    $JBHT
    1/8/2026$240.00Neutral → Positive
    Susquehanna
    Amgen Inc.
    $AMGN
    1/7/2026$380.00Buy
    UBS
    More analyst ratings

    $AMGN
    $AR
    $BK
    $JBHT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Strategic Education Inc.

    SCHEDULE 13G/A - Strategic Education, Inc. (0001013934) (Subject)

    2/17/26 5:26:15 PM ET
    $STRA
    Other Consumer Services
    Real Estate

    SEC Form FWP filed by Amgen Inc.

    FWP - AMGEN INC (0000318154) (Subject)

    2/17/26 5:14:08 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Amgen Inc.

    424B3 - AMGEN INC (0000318154) (Filer)

    2/17/26 8:33:39 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $AR
    $BK
    $JBHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Officer Krueger Brendan E. bought $166,750 worth of shares (5,000 units at $33.35), increasing direct ownership by 2% to 295,917 units (SEC Form 4)

    4/A - ANTERO RESOURCES Corp (0001433270) (Issuer)

    11/10/25 8:14:30 PM ET
    $AR
    Oil & Gas Production
    Energy

    Officer Krueger Brendan E. bought $166,750 worth of shares (5,000 units at $33.35), increasing direct ownership by 2% to 295,917 units (SEC Form 4)

    4 - ANTERO RESOURCES Corp (0001433270) (Issuer)

    11/10/25 4:47:25 PM ET
    $AR
    Oil & Gas Production
    Energy

    CHIEF FINANCIAL OFFICER Jackson Daniel Wayne bought $154,850 worth of shares (1,900 units at $81.50), increasing direct ownership by 2% to 104,136 units (SEC Form 4)

    4 - Strategic Education, Inc. (0001013934) (Issuer)

    9/2/25 11:41:54 AM ET
    $STRA
    Other Consumer Services
    Real Estate

    $AMGN
    $AR
    $BK
    $JBHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and COO Hobbs Nicholas gifted 447 shares, decreasing direct ownership by 0.48% to 92,842 units (SEC Form 4)

    4 - HUNT J B TRANSPORT SERVICES INC (0000728535) (Issuer)

    2/17/26 5:49:58 PM ET
    $JBHT
    Trucking Freight/Courier Services
    Industrials

    Co-President & CCO Hayne Margaret sold $1,028,109 worth of shares (14,574 units at $70.54) (SEC Form 4)

    4 - URBAN OUTFITTERS INC (0000912615) (Issuer)

    2/17/26 4:37:56 PM ET
    $URBN
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    CEO & Chairman of the Board Hayne Richard A sold $2,203,303 worth of shares (31,233 units at $70.54), decreasing direct ownership by 0.10% to 17,483,883 units (SEC Form 4)

    4 - URBAN OUTFITTERS INC (0000912615) (Issuer)

    2/17/26 4:37:40 PM ET
    $URBN
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $AMGN
    $AR
    $BK
    $JBHT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BNY Mellon Investment Adviser, Inc. Announces Portfolio Manager Changes for Municipal Bond Closed-End Funds

    BNY Mellon Investment Adviser, Inc. announced changes to the portfolio management teams for BNY Mellon Strategic Municipal Bond Fund, Inc., BNY Mellon Strategic Municipals, Inc. and BNY Mellon Municipal Bond Infrastructure Fund, Inc. (each, a "Fund"). Each Fund is sub-advised by Insight North America LLC ("INA"), an affiliate of BNY Mellon Investment Adviser, Inc. Effective February 17, 2026, Daniel Rabasco will no longer serve as a portfolio manager of the Funds. Jeffrey Burger will continue to serve as a portfolio manager of each Fund and Thomas Casey will continue to serve as a portfolio manager of BNY Mellon Municipal Bond Infrastructure Fund, Inc. In addition, Mr. Casey has been adde

    2/17/26 11:48:00 AM ET
    $BK
    $DSM
    $LEO
    Major Banks
    Finance
    Investment Managers
    Trusts Except Educational Religious and Charitable

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

    Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer1,3-6HORSHAM, Pa., Feb. 17, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj). When administered in combination with oral LAZCLUZE® (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consis

    2/17/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMGN
    $AR
    $BK
    $JBHT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $AR
    $BK
    $JBHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Visa upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Visa from Neutral to Outperform and set a new price target of $370.00

    2/3/26 7:57:45 AM ET
    $V
    Real Estate

    Visa upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Visa from Neutral to Buy and set a new price target of $385.00

    1/28/26 7:12:10 AM ET
    $V
    Real Estate

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMGN
    $AR
    $BK
    $JBHT
    Leadership Updates

    Live Leadership Updates

    View All

    J.B. Hunt Joins the Triumph Network

    Triumph (NYSE:TFIN), a financial and technology company focused on modernizing and simplifying freight transactions, today announced that J.B. Hunt Transport Services, Inc. (NASDAQ:JBHT) has joined the Triumph Network. J.B. Hunt, one of the largest supply chain solutions providers in North America, will adopt Triumph's advanced automated payment solution to accelerate and streamline carrier payment cycles. "J.B. Hunt's reputation as an innovator in transportation and logistics, combined with their commitment to embracing technology, makes them a true leader in our industry," said Triumph founder and chief executive officer, Aaron P. Graft. "Their decision to join the Triumph Network und

    1/22/26 4:07:00 PM ET
    $JBHT
    $TFIN
    Trucking Freight/Courier Services
    Industrials
    Major Banks
    Finance

    BNY Joins U.S. Government's Investment Initiative for Children, Expanding Access to Savings and Financial Opportunity for Employees

    The company will match federal contributions for eligible U.S. employees' children, strengthening financial access for families NEW YORK, Dec. 11, 2025 /PRNewswire/ -- BNY (NYSE:BK) today announced its participation in the U.S. government's investment initiative for children, continuing the company's long history of expanding financial access and opportunity for employees and their families. As one of the first financial services companies to join the program, BNY will match the federal government's $1,000 contribution for eligible newborns of its eligible U.S. employees, doubling the investment in each child's future.

    12/11/25 11:46:00 AM ET
    $BK
    Major Banks
    Finance

    Visa Foundation Board Appoints Najada Kumbuli as President of Visa Foundation

    Visa (NYSE:V), a global leader in digital payments, today announced that Najada Kumbuli has been appointed President of Visa Foundation, effective immediately. With guidance from the Board, Kumbuli will be responsible for managing Visa Foundation's impact investing and grantmaking, and will also serve as Visa Inc.'s head of global philanthropy. Kumbuli has more than 15 years of experience in investment strategy, impact evaluation, and leadership of global philanthropic programs. Prior to Visa Foundation, she served as the Investment Director at Calvert Impact Capital, a global impact investment firm. Kumbuli succeeds Graham Macmillan, who served as Visa Foundation's president since 2019.

    12/11/25 10:30:00 AM ET
    $V
    Real Estate

    $AMGN
    $AR
    $BK
    $JBHT
    Financials

    Live finance-specific insights

    View All

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Antero Midstream Announces Fourth Quarter 2025 Results and 2026 Guidance

    DENVER, Feb. 11, 2026 /PRNewswire/ -- Antero Midstream Corporation (NYSE:AM) ("Antero Midstream" or the "Company") today announced its fourth quarter 2025 financial and operating results and 2026 guidance.  The relevant consolidated financial statements are included in Antero Midstream's Annual Report on Form 10-K for the year ended December 31, 2025. Fourth Quarter 2025 Highlights: Low pressure gathering and compression volumes increased by 5% compared to the prior year quarterNet Income was $52 million, or $0.11 per diluted share, a 52% per share decrease compared to the pri

    2/11/26 4:15:00 PM ET
    $AM
    $AR
    Natural Gas Distribution
    Utilities
    Oil & Gas Production
    Energy

    Antero Resources Announces Fourth Quarter 2025 Results and 2026 Guidance

    DENVER, Feb. 11, 2026 /PRNewswire/ -- Antero Resources Corporation (NYSE:AR) ("Antero Resources," "Antero," or the "Company") today announced its fourth quarter 2025 financial and operating results, year end 2025 estimated proved reserves and 2026 guidance. The relevant consolidated financial statements are included in Antero Resources' Annual Report on Form 10-K for the year ended December 31, 2025.  Fourth Quarter 2025 Highlights: Net production averaged 3.5 Bcfe/d, 2% increase from the year ago periodRealized a pre-hedge natural gas equivalent price of $3.97 per Mcfe, a $0.

    2/11/26 4:15:00 PM ET
    $AR
    Oil & Gas Production
    Energy

    $AMGN
    $AR
    $BK
    $JBHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

    SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 6:39:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unity Biotechnology Inc.

    SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)

    11/14/24 4:35:22 PM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care